Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.72 |
| ▸ | PGR | P06401 | 14/20 | 0.72 |
| ▸ | AR | P10275 | 11/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20048236 | 0.90 | NR3C1 (0.88) | NR3C1PGRARCYP3A4 | |
| SCHEMBL20048419 | 0.89 | NR3C1 (0.77) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL23381653 | 0.87 | NR3C1 (0.55) | NR3C1PGRARCYP3A4 | |
| SCHEMBL23653625 | 0.87 | NR3C1 (0.61) | NR3C1PGRARCYP3A4 | |
| SCHEMBL20048408 | 0.86 | NR3C1 (0.81) | NR3C1PGRARCYP3A4CYP2C19 | |
| SCHEMBL20048417 | 0.84 | NR3C1 (0.81) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL20048086 | 0.84 | NR3C1 (1.00) | NR3C1PGRARCYP3A4 | |
| SCHEMBL20048341 | 0.84 | NR3C1 (1.00) | NR3C1PGRARCYP3A4 | |
| SCHEMBL20048416 | 0.83 | NR3C1 (0.82) | NR3C1PGRARCYP3A4 | |
| SCHEMBL20048336 | 0.82 | NR3C1 (0.86) | NR3C1PGRARCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302014-A1 | USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST AND ANDROGEN RECEPTOR (AR) DEGRADER COMBINATIONS | ORIC PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-3851444-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3523315-B1 | INHIBITOR OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10836789-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200291058-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10723759-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200055892-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019200156-A1 | SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF | ORIC PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018068021-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20230302014-A1 | USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST AND ANDROGEN RECEPTOR (AR) DEGRADER COMBINATIONS | AR, NR3C1, MC2R | NR3C1 2/4885PGR 31/4885AR 1/4885 |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20200055892-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-10836789-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-10723759-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20200291058-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.